Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00339014 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity
A Phase 2 study, sponsored by Orexigen Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 611
- Enrollment target
NCT00339014 is a Phase 2 study that has completed, run by Orexigen Therapeutics. The registered enrollment target is 611 participants.
The verdict
NCT00339014, a Phase 2 study, has completed, sponsored by Orexigen Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 611 participants
- Enrollment target
Study Summary
The purpose of this study is to determine which of seven combinations of Zonisamide CR and Bupropion SR gives the best weight loss and is safe and well tolerated for the treatment of obesity not associated with the complications of obesity such as diabetes. In a previous study, the combination of zonisamide and bupropion SR was shown to be effective for weight loss compared to either zonisamide, bupropion SR alone or placebo. It is thought that by adjusting the doses of each drug, giving zonisamide in a controlled release (CR) form and increasing the doses more slowly, more weight loss and less side effects can be attained.
Interventions
- OTHER Placebo
- DRUG Zonisamide CR and Bupropion SR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 611 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00339014
The ClinicalTrials.gov registry entry for NCT00339014 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 611 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orexigen Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00339014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00339014 about?
NCT00339014 is a clinical study titled "Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity". The purpose of this study is to determine which of seven combinations of Zonisamide CR and Bupropion SR gives the best weight loss and is safe and well tolerated for the treatment of obesity not associated with the complications of obesity such as diabetes. In a previous study, the combination of zo...
What is the current status of trial NCT00339014?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 611 participants. The study started on 2006-05. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00339014?
The interventions under investigation include: Placebo (OTHER), Zonisamide CR and Bupropion SR (DRUG).
Who is sponsoring clinical trial NCT00339014?
This trial is sponsored by Orexigen Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.